SNOA — Sonoma Pharmaceuticals, Inc.

Sonoma (SNOA) Q2 2019 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $4.9 million, a record high, representing a 14% increase year-over-year and a 13% increase from the previous quarter.
• EBITDA: Loss of $1.95 million, marking a 37% reduction from the prior quarter and a decrease from $2.26 million year-over-year.
• Cash Position: $4 million at quarter-end, down from $7.7 million in the previous quarter, primarily due to operating cash burn and increases in working capital.
• Prescription Volume: 17,410 prescriptions filled, the highest in company history, up 12% year-over-year and 18% from the previous quarter.

2. Strategic Updates and Business Highlights:

• Sonoma is expanding into the acne management market with the launch of the Epicyn Antimicrobial Facial Cleanser in the U.S. and Gramacyn in Brazil, targeting a combined addressable market of approximately $300 million.
• Four out of five business units are profitable, with significant growth in U.S. dermatology and animal healthcare segments.
• The company is addressing gross-to-net issues through improved relationships with pharmacy and managed care partners.
• The mail order pharmacy program has increased to over 40% of unit sales, enhancing distribution and reducing inventory risks.

3. Forward Guidance and Outlook:

• Continued growth in sales rep productivity and expected revenue increases from new product launches.
• Anticipated improvement in profitability as operating expenses are expected to remain flat or decrease due to cost reduction initiatives.
• The company aims to reduce EBITDA losses further while maintaining revenue growth.

4. Bad News, Challenges, or Points of Concern:

• The cash position has decreased significantly, raising concerns about liquidity and operational sustainability.
• The dermatology segment has seen fluctuations, with a noted decline in factory unit shipments compared to the previous year, although there was a quarter-over-quarter increase.
• The company faces ongoing gross-to-net challenges typical in the pharmaceutical industry, which could impact future profitability.

5. Notable Q&A Insights:

• The mail order pharmacy program has successfully grown, now accounting for over 40% of revenues, which helps mitigate inventory reduction risks.
• The Brazilian market is expected to contribute significantly to revenue growth, with the partner exceeding contractual shipment expectations.
• Management confirmed that rebate costs have stabilized, indicating improved control over pricing strategies.

Overall, Sonoma is making progress in its strategic initiatives and financial metrics, but it faces challenges related to cash management and market fluctuations. The outlook remains cautiously optimistic with new product launches and operational improvements.